Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2015

View Archived Issues

Initiation of clinical trial of TLR7 agonist GS-9620 in HIV-positive patients on ART

ISA Pharmaceuticals begins first phase I/II trial of Amplivant conjugates

Biogen Idec and Sobi report topline data from phase III Alprolix pediatric trial

Johnson & Johnson Health and Wellness Solutions formed to encourage well-being and quality of life

Cipher Pharmaceuticals acquires three dermatology products from Astion Pharma

New N-type calcium channel blockers disclosed by Janssen

Investigators at Duke University divulge new LpxC inhibitors

Pacira receives FDA complete response letter for Exparel sNDA

Cadila Healthcare patents new JAK inhibitors

Boehringer Ingelheim discloses new ENaC blockers

Russian and U.S. investigators present new adenosine A2A receptor antagonists

Phase II data lead to phase III initiation for HIV candidate BMS-663068

Abraxane approved by European Commission for first-line treatment of NSCLC

FDA accepts Alexion's BLA for asfotase alfa in hypophosphatasia for priority review

EMA committee recommends approval of Avastin plus chemotherapy for advanced cervical cancer

European Commission approves Xydalba for ABSSSI

Tenofovir alafenamide fumarate subject of several presentations at CROI

Shire submits NDA for lifitegrast for dry eye

Taiho seeks European approval for TAS-102 for metastatic colorectal cancer

FDA accepts for filing Xadago NDA

New clinical trial evaluates ZMapp for Ebola virus

Envelope-specific monoclonal antibodies offer a novel approach for the treatment of HIV infection

Torii gains rights from Japan Tobacco to market Gilead tenofovir alafenamide combinations in Japan

Boehringer Ingelheim files for approval of dabigatran antidote idarucizumab

FDA accepts sBLA for Yervoy in stage III melanoma

CHMP recommends approval of Humira for severe chronic plaque psoriasis in children

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...